The mean leukocyte myeloperoxidase index in hematological patients

P. Froom*, M. Quitt, E. Aghai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

A Technicon H-1 hematologic analyzer was used to measure the mean leukocyte myeloperoxidase (MPX) in 160 patients seen in a hematology clinic. The normal range was -15 to +10, which included 95% of 300 consecutive hospitalized patients. No abnormalities in the MPX were found in 35 patients with beta-thalassemia minor, 8 with iron deficiency, 14 with myeloproliferative disorders, 17 with autoimmune disorders, and 37 patients with lymphoma in complete remission. On the other hand 36% (10/28) of lymphoma patients with active disease either at diagnosis or relapse had a MPX of >10 compared to only 2.3% (7/300) in hospitalized patients (P<0.001). Increased levels of MPX were found primarily in patients with non-Hodgkin's lymphoma (NHL) of intermediate or high grades, or Hodgkin's disease [56% (9/16) compared to only 8.3% (1/12) in those with low grade NHLs, P < 0.05]. The MPX levels returned to normal after successful treatment. Of the various chemotherapeutic agents used, only hydroxyurea led to a consistent elevation of the MPX. The authors conclude that MPX is commonly increased in patients with lymphoma and in those receiving hydroxyurea. Further studies are required to determine if the MPX is a sensitive test for relapse in patients with lymphomas who had an elevated pretreatment value.

Original languageEnglish
Pages (from-to)791-793
Number of pages3
JournalAmerican Journal of Clinical Pathology
Volume92
Issue number6
DOIs
StatePublished - 1989
Externally publishedYes

Keywords

  • hydroxyurea
  • lymphoma
  • myeloperoxidase

Fingerprint

Dive into the research topics of 'The mean leukocyte myeloperoxidase index in hematological patients'. Together they form a unique fingerprint.

Cite this